[HTML][HTML] In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications
A Refaat, ML Yap, G Pietersz, APG Walsh… - Journal of …, 2022 - Springer
… review, we discuss the latest advances in in vivo fluorescence imaging technologies, NIR
fluorescent probes, and current and future clinical applications… or monoclonal antibodies (mAb) …
fluorescent probes, and current and future clinical applications… or monoclonal antibodies (mAb) …
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis
K Drellia, L Kokoti, CI Deligianni… - …, 2021 - journals.sagepub.com
… The selection of anti-CGRP mAbs comparators was based on three … of their clinical evaluation
program, the timing of clinical testing, and finally their frequency of use in current clinical …
program, the timing of clinical testing, and finally their frequency of use in current clinical …
[HTML][HTML] Phage display technology as a powerful platform for antibody drug discovery
K Nagano, Y Tsutsumi - Viruses, 2021 - mdpi.com
… Here, we review the importance of … monoclonal antibodies with high specificity and affinity
to target molecules were expected to be used as magic bullets for various clinical applications […
to target molecules were expected to be used as magic bullets for various clinical applications […
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
… Tocilizumab is a humanized monoclonal antibody (mAb) that targets IL-6R as outlined …
Sirukumab (formerly known as CNTO 136) is a human anti-IL-6 monoclonal antibody developed …
Sirukumab (formerly known as CNTO 136) is a human anti-IL-6 monoclonal antibody developed …
Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation
V Chugh, K Vijaya Krishna, A Pandit - ACS nano, 2021 - ACS Publications
… In this review, we focus on providing a detailed insight into the … an overview of different cell
types, their inherent biological properties, and suitability for specific therapeutic applications …
types, their inherent biological properties, and suitability for specific therapeutic applications …
Broad neutralization of SARS-related viruses by human monoclonal antibodies
… Studies of convalescent sera and a limited number of monoclonal antibodies (mAbs) have
revealed limited to no cross-neutralizing activity, demonstrating that conserved antigenic sites …
revealed limited to no cross-neutralizing activity, demonstrating that conserved antigenic sites …
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
… the use of antiviral monoclonal antibodies of covid-19.… therapeutic applications in the
treatment of congenital and acquired diseases,8 one can, in the absence of clear evidence for use …
treatment of congenital and acquired diseases,8 one can, in the absence of clear evidence for use …
Viral vector‐based gene therapies in the clinic
… 13 approved products and their clinical applications. We have … Here, we provide an overview
of clinical advances of viral … protein, VRC07 human monoclonal antibody, are studied in …
of clinical advances of viral … protein, VRC07 human monoclonal antibody, are studied in …
[HTML][HTML] Potential therapeutic options for COVID-19: an update on current evidence
… In this review, the current evidence of potential therapeutic … on the antibody include neutralizing
monoclonal antibodies, and … These therapeutic approachs and their clinical application …
monoclonal antibodies, and … These therapeutic approachs and their clinical application …
[HTML][HTML] Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
… neutralizing monoclonal antibodies that are in clinical use … review information Nature thanks
Patrick Wilson and the other, anonymous, reviewers for their contribution to the peer review …
Patrick Wilson and the other, anonymous, reviewers for their contribution to the peer review …